GB201702250D0 - Method - Google Patents

Method

Info

Publication number
GB201702250D0
GB201702250D0 GBGB1702250.0A GB201702250A GB201702250D0 GB 201702250 D0 GB201702250 D0 GB 201702250D0 GB 201702250 A GB201702250 A GB 201702250A GB 201702250 D0 GB201702250 D0 GB 201702250D0
Authority
GB
United Kingdom
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1702250.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acacia Pharma Ltd
Original Assignee
Acacia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd
Priority to GBGB1702250.0A priority Critical patent/GB201702250D0/en
Publication of GB201702250D0 publication Critical patent/GB201702250D0/en
Priority to NZ796242A priority patent/NZ796242B2/en
Priority to KR1020197023506A priority patent/KR20190111993A/ko
Priority to CA3052535A priority patent/CA3052535C/en
Priority to JP2019543311A priority patent/JP7333269B2/ja
Priority to CN202610317207.4A priority patent/CN122351229A/zh
Priority to KR1020237044292A priority patent/KR20240001288A/ko
Priority to PCT/GB2018/050374 priority patent/WO2018146490A1/en
Priority to IL268591A priority patent/IL268591B2/en
Priority to US16/485,008 priority patent/US11357753B2/en
Priority to NZ756051A priority patent/NZ756051B2/en
Priority to EP18705483.8A priority patent/EP3579831A1/en
Priority to MX2019009507A priority patent/MX388736B/es
Priority to EA201991667A priority patent/EA201991667A1/ru
Priority to CN201880011444.1A priority patent/CN110603036A/zh
Priority to AU2018218310A priority patent/AU2018218310B2/en
Priority to IL298486A priority patent/IL298486B2/en
Priority to BR112019016565-7A priority patent/BR112019016565A2/pt
Priority to ZA2019/05212A priority patent/ZA201905212B/en
Priority to US17/746,032 priority patent/US12005042B2/en
Priority to JP2022196161A priority patent/JP7526244B2/ja
Priority to US18/653,318 priority patent/US12329740B2/en
Priority to AU2024203155A priority patent/AU2024203155B2/en
Priority to US19/211,545 priority patent/US20250367211A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1702250.0A 2017-02-10 2017-02-10 Method Ceased GB201702250D0 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
GBGB1702250.0A GB201702250D0 (en) 2017-02-10 2017-02-10 Method
BR112019016565-7A BR112019016565A2 (pt) 2017-02-10 2018-02-09 Tratamento de emergência de náuseas e vômitos pós-operatórios
NZ756051A NZ756051B2 (en) 2018-02-09 Rescue treatment of post operative nausea and vomiting
MX2019009507A MX388736B (es) 2017-02-10 2018-02-09 Tratamiento de rescate de nausea y vomito post operatorio.
CA3052535A CA3052535C (en) 2017-02-10 2018-02-09 Rescue treatment of post operative nausea and vomiting
JP2019543311A JP7333269B2 (ja) 2017-02-10 2018-02-09 術後悪心嘔吐の救援治療
CN202610317207.4A CN122351229A (zh) 2017-02-10 2018-02-09 术后恶心和呕吐的补救治疗
KR1020237044292A KR20240001288A (ko) 2017-02-10 2018-02-09 수술 후 오심 및 구토의 구제 치료
PCT/GB2018/050374 WO2018146490A1 (en) 2017-02-10 2018-02-09 Rescue treatment of post operative nausea and vomiting
IL268591A IL268591B2 (en) 2017-02-10 2018-02-09 Rescue treatment after activity of nausea and vomiting
US16/485,008 US11357753B2 (en) 2017-02-10 2018-02-09 Rescue treatment of post operative nausea and vomiting
NZ796242A NZ796242B2 (en) 2018-02-09 Rescue treatment of post operative nausea and vomiting
EP18705483.8A EP3579831A1 (en) 2017-02-10 2018-02-09 Rescue treatment of post operative nausea and vomiting
KR1020197023506A KR20190111993A (ko) 2017-02-10 2018-02-09 수술 후 오심 및 구토의 구제 치료
EA201991667A EA201991667A1 (ru) 2017-02-10 2018-02-09 Экстренное лечение постоперационной тошноты и рвоты
CN201880011444.1A CN110603036A (zh) 2017-02-10 2018-02-09 术后恶心和呕吐的补救治疗
AU2018218310A AU2018218310B2 (en) 2017-02-10 2018-02-09 Rescue treatment of post operative nausea and vomiting
IL298486A IL298486B2 (en) 2017-02-10 2018-02-09 Rescue treatment of post operative nausea and vomiting
ZA2019/05212A ZA201905212B (en) 2017-02-10 2019-08-07 Rescue treatment of post operative nausea and vomiting
US17/746,032 US12005042B2 (en) 2017-02-10 2022-05-17 Rescue treatment of post operative nausea and vomiting
JP2022196161A JP7526244B2 (ja) 2017-02-10 2022-12-08 術後悪心嘔吐の救援治療
US18/653,318 US12329740B2 (en) 2017-02-10 2024-05-02 Rescue treatment of post operative nausea and vomiting
AU2024203155A AU2024203155B2 (en) 2017-02-10 2024-05-13 Rescue treatment of post operative nausea and vomiting
US19/211,545 US20250367211A1 (en) 2017-02-10 2025-05-19 Rescue treatment of post operative nausea and vomiting

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1702250.0A GB201702250D0 (en) 2017-02-10 2017-02-10 Method

Publications (1)

Publication Number Publication Date
GB201702250D0 true GB201702250D0 (en) 2017-03-29

Family

ID=58462198

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1702250.0A Ceased GB201702250D0 (en) 2017-02-10 2017-02-10 Method

Country Status (13)

Country Link
US (4) US11357753B2 (cg-RX-API-DMAC7.html)
EP (1) EP3579831A1 (cg-RX-API-DMAC7.html)
JP (2) JP7333269B2 (cg-RX-API-DMAC7.html)
KR (2) KR20190111993A (cg-RX-API-DMAC7.html)
CN (2) CN122351229A (cg-RX-API-DMAC7.html)
AU (2) AU2018218310B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019016565A2 (cg-RX-API-DMAC7.html)
EA (1) EA201991667A1 (cg-RX-API-DMAC7.html)
GB (1) GB201702250D0 (cg-RX-API-DMAC7.html)
IL (2) IL268591B2 (cg-RX-API-DMAC7.html)
MX (1) MX388736B (cg-RX-API-DMAC7.html)
WO (1) WO2018146490A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201905212B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
IT201900013524A1 (it) * 2019-07-31 2021-01-31 Laboratori Baldacci Spa Nuove formulazioni di amisulpride
BR112023000167A2 (pt) * 2020-07-06 2023-01-31 Acacia Pharma Ltd Terapia de náusea e vômito pós-operatórios

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1004020A (en) 1964-04-24 1965-09-08 Standard Telephones Cables Ltd Improvements in or relating to the mounting of electrical components
FR2415099A1 (fr) 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
GB9305593D0 (en) 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
US6169094B1 (en) 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
DE10163421A1 (de) 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
TWI355936B (en) 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
DE102005013726A1 (de) 2005-03-22 2006-09-28 Grünenthal GmbH Transdermale therapeutische Systeme mit verbesserter Verträglichkeit
GB0506800D0 (en) 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
US8551986B2 (en) 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
JP5433236B2 (ja) 2006-01-27 2014-03-05 アプタリス ファーマテック,インコーポレイテッド 弱塩基性選択性セロトニン5−ht3遮断剤および有機酸を含む薬物送達系
WO2007096489A1 (fr) 2006-02-17 2007-08-30 Trimaran Limited Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
US7825156B2 (en) 2007-02-02 2010-11-02 Copharms Method of treating bipolar depression with a benzamide derivative
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
WO2009126931A2 (en) 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
US20110003005A1 (en) 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
PE20121483A1 (es) 2009-11-18 2012-12-02 Helsinn Healthcare Sa Composiciones para tratar nausea y vomito centralmente mediados
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
AU2011268073B2 (en) 2010-06-18 2015-07-16 Takeda Pharmaceutical Company Limited D2 antagonists, methods of synthesis and methods of use
JP2016532660A (ja) 2013-10-08 2016-10-20 イノファーマ インク アプレピタント経口液体製剤
GB201506116D0 (en) * 2015-04-10 2015-05-27 Acacia Pharma Ltd Kit and combination therapy for nausea and vomiting
GB201618425D0 (en) 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method

Also Published As

Publication number Publication date
US11357753B2 (en) 2022-06-14
BR112019016565A2 (pt) 2020-03-31
US12005042B2 (en) 2024-06-11
IL268591B2 (en) 2023-04-01
JP2020506209A (ja) 2020-02-27
AU2018218310B2 (en) 2024-02-15
IL298486A (en) 2023-01-01
AU2024203155A1 (en) 2024-05-30
IL268591B (en) 2022-12-01
CN122351229A (zh) 2026-07-10
US20250367211A1 (en) 2025-12-04
JP7526244B2 (ja) 2024-07-31
KR20190111993A (ko) 2019-10-02
IL298486B2 (en) 2024-09-01
AU2018218310A1 (en) 2019-08-22
IL268591A (en) 2019-09-26
MX388736B (es) 2025-03-20
AU2024203155B2 (en) 2025-03-13
US20230100786A1 (en) 2023-03-30
CN110603036A (zh) 2019-12-20
ZA201905212B (en) 2023-12-20
US20200038369A1 (en) 2020-02-06
WO2018146490A1 (en) 2018-08-16
NZ756051A (en) 2024-04-26
JP7333269B2 (ja) 2023-08-24
EA201991667A1 (ru) 2020-02-11
US20240285579A1 (en) 2024-08-29
JP2023027213A (ja) 2023-03-01
EP3579831A1 (en) 2019-12-18
IL298486B1 (en) 2024-05-01
KR20240001288A (ko) 2024-01-03
NZ796242A (en) 2026-01-30
CA3052535A1 (en) 2018-08-16
US12329740B2 (en) 2025-06-17

Similar Documents

Publication Publication Date Title
GB201701109D0 (en) Method
GB201710815D0 (en) Method
GB201706778D0 (en) Method
GB201704847D0 (en) Callibration method
GB201709333D0 (en) Method
GB201706544D0 (en) Method
GB201708853D0 (en) Method
GB201917108D0 (en) Method
GB201710812D0 (en) Method
GB201700352D0 (en) Method
GB201711066D0 (en) Method
GB201707140D0 (en) Method
GB201705897D0 (en) Method
GB201715928D0 (en) Method
GB201714645D0 (en) Method
GB201703898D0 (en) Method
GB201709387D0 (en) Method
GB201706079D0 (en) Method
GB201715372D0 (en) Method
GB201705444D0 (en) Method
GB201704913D0 (en) Method
GB201704536D0 (en) Method
GB201702096D0 (en) Method
GB201701941D0 (en) Method
GB201715251D0 (en) Method

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)